Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis
Open Access
- 12 July 2018
- journal article
- research article
- Published by S. Karger AG in Liver Cancer
- Vol. 8 (4) , 281-294
Abstract
Background and Aims: Stereotactic body radiation therapy (SBRT) has emerged as a safe and effective treatment for patients with hepatocellular carcinoma (HCC), but its role in patients with advanced HCC is not yet defined. In this study, we aim to assess the efficacy and safety of SBRT in comparison to sorafenib treatment in patients with advanced HCC. Methods: We included 901 patients treated with sorafenib at six tertiary centers in Europe and Asia and 122 patients treated with SBRT from 13 centers in Germany and Switzerland. Medical records were reviewed including laboratory parameters, treatment characteristics and development of adverse events. Propensity score matching was performed to adjust for differences in baseline characteristics. The primary endpoint was overall survival (OS) and progression-free survival. Results: Median OS of SBRT patients was 18.1 (10.3–25.9) months compared to 8.8 (8.2–9.5) in sorafenib patients. After adjusting for different baseline characteristics, the survival benefit for patients treated with SBRT was still preserved with a median OS of 17.0 (10.8–23.2) months compared to 9.6 (8.6–10.7) months in sorafenib patients. SBRT treatment of intrahepatic lesions in patients with extrahepatic metastases was also associated with improved OS compared to patients treated with sorafenib in the same setting (17.0 vs. 10.0 months, p = 0.012), whereas in patients with portal vein thrombosis there was no survival benefit in patients with SBRT. Conclusions: In this retrospective comparative study, SBRT showed superior efficacy in HCC patients compared to patients treated with sorafenib.Keywords
This publication has 56 references indexed in Scilit:
- Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: a case reportJournal of Medical Case Reports, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- 21 years of Biologically Effective DoseBritish Journal of Radiology, 2010
- Radiotherapy as a bridge to liver transplantation for hepatocellular carcinomaTransplant International, 2010
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- An Overview of Hypofractionation and Introduction to This Issue of Seminars in Radiation OncologySeminars in Radiation Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaJournal of Clinical Oncology, 2008
- Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosisHepatology, 2007
- Management of Hepatocellular Carcinoma *Hepatology, 2005